Furthermore, French investigators recently presented real-world data (RWD) on the management of women with advanced breast cancer and showed that the survival rates have improved impressively for the HER2+ group of patients, with contemporary survival rates higher than 50 months. This evidence concerns the gene ERBB2 and breast cancer.